Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Overview 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Companies Involved in Therapeutics Development Bristol-Myers Squibb Co Corvus Pharmaceuticals Inc Innate Pharma SA MedImmune LLC Surface Oncology Inc 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Drug Profiles AB-680 - Drug Profile Product Description Mechanism Of Action R&D Progress Antibody to Inhibit CD73 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Antibody to Inhibit CD73 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress BMS-986179 - Drug Profile Product Description Mechanism Of Action R&D Progress CPX-006 - Drug Profile Product Description Mechanism Of Action R&D Progress durvalumab + oleclumab - Drug Profile Product Description Mechanism Of Action R&D Progress IPH-53 - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibody to Inhibit CD73 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibody to Inhibit CD73 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress oleclumab - Drug Profile Product Description Mechanism Of Action R&D Progress PBF-1509 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit CD73 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit CD73 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Dormant Products 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Product Development Milestones Featured News & Press Releases Dec 19, 2016: Surface Oncology Announces Collaboration with Dr. John Stagg, a World-Leader in the Adenosine Pathway Apr 18, 2016: Innate Pharma presents new CD73 checkpoint inhibitor program Feb 24, 2014: CD73 Research Could Lead to Cancer Drug Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development by Stage of Development, H1 2018 Number of Products under Development by Therapy Areas, H1 2018 Number of Products under Development by Indication, H1 2018 Number of Products under Development by Companies, H1 2018 Products under Development by Companies, H1 2018 Number of Products under Investigation by Universities/Institutes, H1 2018 Products under Investigation by Universities/Institutes, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Stage and Route of Administration, H1 2018 Number of Products by Stage and Molecule Type, H1 2018 Pipeline by Bristol-Myers Squibb Co, H1 2018 Pipeline by Corvus Pharmaceuticals Inc, H1 2018 Pipeline by Innate Pharma SA, H1 2018 Pipeline by MedImmune LLC, H1 2018 Pipeline by Surface Oncology Inc, H1 2018 Dormant Projects, H1 2018 List of Figures Number of Products under Development by Stage of Development, H1 2018 Number of Products under Development by Indications, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Routes of Administration, H1 2018 Number of Products by Stage and Routes of Administration, H1 2018 Number of Products by Molecule Types, H1 2018 Number of Products by Stage and Molecule Types, H1 2018

Bristol-Myers Squibb Co Corvus Pharmaceuticals Inc Innate Pharma SA MedImmune LLC Surface Oncology Inc